• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 9:52:08 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADMP alert in real time by email
    SC 13G/A 1 tm216476d21_sc13ga.htm SCHEDULE 13G/A

     

    CUSIP No:   00547W208

     

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Adamis Pharmaceuticals Corporation

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    00547W208

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

     

     *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No:   00547W208

     

    (1) NAMES OF REPORTING PERSONS
     
      CVI Investments, Inc.
     
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
     
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Cayman Islands

     

    NUMBER OF   (5) SOLE VOTING POWER
           
    SHARES     0
           
    BENEFICIALLY   (6) SHARED VOTING POWER **
           
         

    4,918,972

    OWNED BY      
           
    EACH   (7) SOLE DISPOSITIVE POWER
           
    REPORTING     0
           
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
           
         

    4,918,972

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    4,918,972

       
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ¨
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
       
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   00547W208

     

    (1) NAMES OF REPORTING PERSONS
     
      Heights Capital Management, Inc.
       
    (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
      (a)       ¨
      (b)       ¨
       
    (3) SEC USE ONLY
     
    (4) CITIZENSHIP OR PLACE OF ORGANIZATION
     
      Delaware

     

    NUMBER OF   (5) SOLE VOTING POWER
     
    SHARES     0
     
    BENEFICIALLY   (6) SHARED VOTING POWER **
     
    OWNED BY    

    4,918,972

         

     

    EACH   (7) SOLE DISPOSITIVE POWER
     
    REPORTING     0
         
     
    PERSON WITH   (8) SHARED DISPOSITIVE POWER **
     
         

    4,918,972

     

     

    (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
       

    4,918,972

         
     
    (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      ¨
       
       
    (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
        4.9%
         
    (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      CO
       

    ** Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over these shares.

     

     

     

     

    CUSIP No:   00547W208

     

    Item 1.

     

    (a)Name of Issuer

     

    Adamis Pharmaceuticals Corporation (the “Company”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    11682 El Camino Real, Suite 300, San Diego, CA 92130

     

    Item 2(a).Name of Person Filing

     

    This statement is filed by the entities listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the shares of common stock of the Company, $0.0001 par value per share (the “Shares”).

     

    (i)CVI Investments, Inc.

     

    (ii)Heights Capital Management, Inc.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The address of the principal business office of CVI Investments, Inc. is:

     

    P.O. Box 309GT 

    Ugland House

    South Church Street

    George Town

    Grand Cayman

    KY1-1104 

    Cayman Islands

     

    The address of the principal business office of Heights Capital Management, Inc. is:

     

    101 California Street, Suite 3250 

    San Francisco, California 94111

     

    Item 2(c).Citizenship

     

    Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    Item 2(d)Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    00547W208

     

     

     

     

    CUSIP No:   00547W208

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);

     

    (k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ________________

     

    Item 4.Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

    The number of Shares reported as beneficially owned consists of Shares issuable upon the exercise of warrants to purchase Shares (the “Warrants”). The Warrants are not exercisable to the extent that the total number of Shares then beneficially owned by a Reporting Person and its affiliates and any other persons whose beneficial ownership of Shares would be aggregated with such Reporting Person for purposes of Section 13(d) of the Exchange Act, would exceed 4.99%.

     

    The Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 indicates there were 93,657,628 Shares outstanding as of November 5, 2020.

     

    Heights Capital Management, Inc., which serves as the investment manager to CVI Investments, Inc., may be deemed to be the beneficial owner of all Shares owned by CVI Investments, Inc. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

     

     

     

    CUSIP No:   00547W208

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control

    Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No:   00547W208

     

    SIGNATURES

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

     

    Dated: February 10, 2021    
         
         
    CVI INVESTMENTS, INC.   HEIGHTS CAPITAL MANAGEMENT, INC.
         
    By: Heights Capital Management, Inc.   By: /s/ Brian Sopinsky
    pursuant to a Limited Power of   Name:  Brian Sopinsky
    Attorney, a copy of which was   Title:  Secretary
    previously filed      
       
    By: /s/ Brian Sopinsky    
    Name:  Brian Sopinsky    
    Title:  Secretary    
             

     

     

     

     

    CUSIP No:   00547W208

     

    EXHIBIT INDEX

     

    EXHIBIT DESCRIPTION
    I Limited Power of Attorney*
    II Joint Filing Agreement*
       
    * Previously filed 

     

     

     

    Get the next $ADMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADMP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Dorbin John W. Jr.

      4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)

      11/2/23 4:50:52 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Dorbin John W. Jr.

      3 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)

      11/2/23 4:31:52 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Cohen Seth

      4 - DMK PHARMACEUTICALS Corp (0000887247) (Issuer)

      10/25/23 5:18:34 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    SEC Filings

    See more
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      2/7/24 5:19:44 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Bankruptcy or Receivership, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      2/5/24 9:00:57 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DMK PHARMACEUTICALS Corp (0000887247) (Filer)

      1/31/24 5:17:31 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      SAN DIEGO, Aug. 21, 2023 (GLOBE NEWSWIRE) --  Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. Q2 2023 Corporate Highlights In May, the Company closed the merger with DMK Pharmaceuticals Corporation (DMK), a private, clinical-stage biotechnology company at the forefront of endorphin-inspired drug design focused on developing novel treatments for opioid use disorder and other neuro-based diseases. Ebrahim Versi, MD, PhD, CEO of DMK, was named CEO of Adamis and Chairman of the Board of Directors. David J. Margu

      8/21/23 9:15:00 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering

      SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the closing of its public offering of 5,930,000 units, with each unit consisting of one share of common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase one share of common stock. Each unit was sold at a public offering price of $1.35. The common warrants are immediately exercisable at a price of $1.35 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants were only purchasable together in this offering, but

      8/4/23 1:43:44 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering

      SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company, today announced the pricing of its public offering of 5,930,000 units at a public offering price of $1.35 per unit. Each unit consists of one share of common stock (or a prefunded warrant in lieu thereof) and one warrant to purchase one share of common stock. The common warrants will be immediately exercisable at an exercise price of $1.35 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, b

      8/2/23 8:30:00 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

      Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

      10/18/21 11:55:40 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

      Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

      6/30/21 5:11:48 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group resumed coverage on Adamis Pharmaceuticals

      Maxim Group resumed coverage of Adamis Pharmaceuticals with a rating of Hold

      1/24/21 2:54:17 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    Leadership Updates

    Live Leadership Updates

    See more
    • Adamis Pharmaceuticals Issues Letter to Stockholders

      SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio. ADAMIS HAS NEW LEADERSHIP COMMITTED TO ENHANCING SHAREHOLDER VALUE YOUR SUPPORT AT THE ANNUAL MEETING IS CRITICAL TO OUR FUTURE SUCCESS July 21, 2022 Dear Fellow Stockholder: Thank you for your ongoing investment in Adamis Pharmaceuticals Corporation ("we," "our," "Adamis" or the "Company"). Like

      7/21/22 7:30:00 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Appoints Vickie Reed to Board of Directors

      SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Vickie Reed as a new director and member of the company's board of directors. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertise as a healthcare executive in financial leadership roles at several public companies, and extensive background in finance and accounting, combined with her experience as a director of another public life science company, should allow her to have an immediate positive impact as Adamis exec

      5/26/22 4:05:00 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth

      David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed President and Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has re

      5/18/22 5:00:00 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    Financials

    Live finance-specific insights

    See more
    • Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

      SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, May 15, 2023 at 2:00 p.m. Pacific Time to discuss its financial and operating results for the first quarter 2023 as well as provide a corporate update, which may include an update concerning the results of the company's special meeting of stockholders scheduled to be held on May 15, 2023 at 10:00 a.m. Pacific Time as we

      5/8/23 4:05:00 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

      SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company's fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its websi

      3/14/23 4:01:00 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease, today reported financial results for the third quarter of 2022 and provided an update on recent corporate developments. Process Update In October, the Company announced that it had initiated a process to explore a range of strategic and financing alternatives and had retained an investment bank to assist in evaluating certain alternatives focused on maximizing stockholder value. Potential

      11/14/22 4:10:07 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Adamis Pharmaceuticals Corporation (Amendment)

      SC 13G/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)

      2/6/24 10:04:02 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Adamis Pharmaceuticals Corporation (Amendment)

      SC 13D/A - DMK PHARMACEUTICALS Corp (0000887247) (Subject)

      9/26/23 8:37:00 AM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Adamis Pharmaceuticals Corporation

      SC 13G - Adamis Pharmaceuticals Corp (0000887247) (Subject)

      8/10/23 4:03:30 PM ET
      $ADMP
      Biotechnology: Pharmaceutical Preparations
      Health Care